With over 30 years of experience in research and drug discovery, Thomas Hanke is Executive Vice President and Head of Academic Partnerships at Evotec.
Thomas leads the development of strategic academic collaborations, oversees pre-seed incubators, and manages investments in spin-out companies.
Previously, Thomas was responsible for Evotec’s drug discovery portfolio in inflammation and immuno-oncology, driving high-value, performance-based alliances with academia and pharmaceutical companies. He currently serves on the boards of Dark Blue Therapeutics, CARMA Fund I, Tubulis, and Argobio (observer). Additionally, he co-leads the ‘Technology Transfer’ working group at BIO Deutschland.
Before joining Evotec, Thomas was Sourcing Director at Novo Nordisk’s Biopharmaceuticals Research Unit and co-founder and Chief Scientific Officer of TeGenero, where he led the development of first-in-class immunomodulatory monoclonal antibodies. He holds a PhD in Biology from the University of Würzburg, where he was also a group leader and Assistant Professor in Immunobiology.